Hicks B H, Finer N, Herbert L C
Acta Endocrinol (Copenh). 1984 Dec;107(4):439-44. doi: 10.1530/acta.0.1070439.
The results of this study offer further evidence that metergoline is a valuable alternative to bromocriptine in the suppression of excessive prolactin secretion. Forty-nine hyperprolactinaemic and 44 normoprolactinaemic women with amenorrhoea took part in a double-blind trial to compare the efficacy of metergoline 12 mg/day and bromocriptine 7.5 mg/day in restoring menstruation and ovulation. All the women had normal results on conventional tomography of the sella turcica, normal gonadotrophin levels and normal androgen levels. In the hyperprolactinaemic group, metergoline and bromocriptine were equally effective, with 84 and 75% respectively achieving menstruation, and 76 and 67% respectively achieving ovulation, within 4 months. In the normoprolactinaemic group, 47% menstruated and 40% ovulated on metergoline, against comparative figures of 36 and 21% for bromocriptine and 20 and 13% for placebo, but the differences were not statistically significant. Side effects were not a major problem.
本研究结果进一步证明,在抑制泌乳素过度分泌方面,麦角苄酯是溴隐亭的一种有价值的替代药物。49名高泌乳素血症闭经女性和44名正常泌乳素血症闭经女性参与了一项双盲试验,以比较每日服用12毫克麦角苄酯和7.5毫克溴隐亭恢复月经和排卵的疗效。所有女性蝶鞍常规断层扫描结果正常、促性腺激素水平正常且雄激素水平正常。在高泌乳素血症组中,麦角苄酯和溴隐亭疗效相当,4个月内分别有84%和75%的患者恢复月经,76%和67%的患者恢复排卵。在正常泌乳素血症组中,服用麦角苄酯的患者有47%恢复月经,40%恢复排卵,而服用溴隐亭的相应比例为36%和21%,服用安慰剂的相应比例为20%和13%,但差异无统计学意义。副作用不是主要问题。